Sign in to view content

Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials

Karl G. Csaky, MD, PhD

Video
Published 2021

Related

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Fluctuations in Central Foveal Thickness and Vision Outcomes With AntiVEGF Therapy for Neovascular Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Updates from the Field
2020
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more